Cesca Therapeutics, Inc. (NASDAQ: KOOL) is engaged in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. The company is focused on developing and manufacturing automated blood and bone marrow processing systems that enable the … Continue reading →

Guided Therapeutics, Inc. (OTC: GTHP) has developed a biophotonic technology for the early detection of disease that leads to cancer. The technology uses light to detect disease at the cellular level and provide immediate results at the time of the … Continue reading →

Can-Fite BioPharma Ltd. (NYSE: CANF) is an Israeli biopharmaceutical company with pharmaceutical discovery and clinical development stage capabilities, developing treatments for cancer, inflammatory disease, and sexual dysfunction. The company’s CF101 drug candidate is currently under advanced clinical development, preparing to … Continue reading →

Celator Pharmaceuticals, Inc. (NASDAQ: CPXX) is a clinical-stage biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer. Celator’s proprietary technology platform, CombiPlex, enables the rational design and rapid evaluation of … Continue reading →

Intec Pharma Ltd. (NASDAQ: NTEC) is developing drugs based on its proprietary Accordion Pill platform technology. Accordion Pill is an oral drug delivery system designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing … Continue reading →

Amedica Corp. (NASDAQ: AMDA) develops Silicon Nitride orthopedic and spinal implants. It is the only company that has FDA approval to produce and distribute medical grade Silicon Nitride. Amedica’s line of Silicone Nitride Interbody Fusion implants are designed to participate … Continue reading →

Axsome Therapeutics, Inc. (Nasdaq: AXSM) is a clinical stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous system, or CNS, disorders. By focusing on this therapeutic area, the company is addressing significant and growing … Continue reading →

Resverlogix Corp. (OTC: RVXCF) is an epigenetics company, creating small molecule therapeutics for BET inhibition. The company is currently developing apabetalone (RVX-208), a first-in-class, small molecule selective BET bromodomain inhibitor. It is the only selective BET bromodomain inhibitor in clinical … Continue reading →

Bionomics Ltd. (OTC: BNOEF) is a fully integrated, international drug discovery and development company creating new therapies that serve large unmet needs in cancer and central nervous system disorders such as depression, anxiety and Alzheimer’s. Bionomics has created proprietary technology … Continue reading →

CorMedix, Inc. (NYSE: CRMD) is a commercial-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases. The company’s first commercial product in Europe is Neutrolin®, a catheter … Continue reading →